Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award

Posted on by Pencis

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award 

RWTH Aachen University | Germany

AUTHOR PROFILE

Scopus

Google Scholar

Orcid ID

EARLY ACADEMIC PURSUITS

Priv.-Doz. Dr. rer. nat. Matthias Bartneck embarked on his academic journey with a diploma in Biology from the University of Bielefeld (2001-2006). His diploma thesis focused on gene expression and metabolite profiling of human primary mamma carcinomas, under the supervision of Dr. Anke Becker. He continued his academic pursuits with a Doctor of Natural Sciences degree from RWTH Aachen (2007-2010), where his research centered on the interactions of human primary immune cells with various nanomaterials. This work was supervised by Prof. Gabriele Zwadlo-Klarwasser.

PROFESSIONAL ENDEAVORS

Dr. Bartneck’s professional career has been marked by a series of significant positions and collaborations. He has been employed at the Medical Faculty 10, Gastroenterology, and Faculty 1 Leibniz Institute for Interactive Materials DWI/RWTH Institute for Technical and Macromolecular Chemistry (ITMC) since 2023. He has also served as a guest lecturer at the Max Planck Research Training School Matter to Life. From 2018 to 2022, he was a lecturer at the Center for Functional Magnetic Materials, Immanuel Kant Baltic Federal University in Kaliningrad, Russia. Additionally, Dr. Bartneck has been a group leader at the Medical Faculty, Medical Clinic III, RWTH Aachen since 2014, focusing on immunomodulatory nanomedicine for inflammatory diseases and cancer.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER THERAPY

Dr. Bartneck’s research has significantly advanced the fields of gastroenterology, hepatology, and nanomedicine. His work has delved into the development of novel nanocarriers for treating liver diseases and cancer, as well as the modulation of immune cell migration and activation in inflammatory diseases. His research has been supported by substantial funding, including grants from the German Research Foundation (DFG) and the Wilhelm Sander Foundation. His contributions include over 61 publications, 18 as the first author and 4 as the last author, along with 7 book chapters and 9 reviews.

CITATIONS

  • Zitate           4439
  • h-index        35
  • i10-index     49

IMPACT AND INFLUENCE

Dr. Bartneck’s research has had a profound impact on the scientific community, evidenced by a total of 3764 citations and an H-index of 32. His expertise in immunomodulatory nanomedicine has led to collaborations with prestigious institutions and industry partners, including Bayer Healthcare, Novartis, and Precision Nanosystems. His work has been recognized with several fellowships and awards, such as the Young Investigator Award from the European Association for the Study of the Liver (EASL).

ACADEMIC CITES

Dr. Bartneck has held numerous academic positions and provided significant contributions to teaching and mentoring. He has supervised a wide range of students, from bachelor to doctoral levels, across multiple disciplines including medicine, chemistry, and biology. His teaching roles have included lectures and practical courses in materials science, blood and defense, and inflammation at RWTH Aachen.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Bartneck’s legacy is marked by his interdisciplinary approach and dedication to advancing nanomedicine and immunology. He has secured research funds exceeding €1,500,000 in 2022 alone for the development of novel lipid-based nucleic acid therapeutics. His future contributions are expected to further enhance the understanding and treatment of inflammation-associated diseases and cancer. His continued collaborations with international academic and industry partners underscore his commitment to advancing scientific knowledge and innovation.

NOTABLE PUBLICATION:

Citation: 08         Year: 2022

Citation: 01        Year: 2023

 

Prof Lubna Tahtamouni | Cancer Cell Biology | Best Researcher Award 

Posted on by Pencis

Prof Lubna Tahtamouni | Cancer Cell Biology | Best Researcher Award 

The Hashemite University | Jordan

Author Profile

Scopus

Scholar

Orcid ID

Early Academic Pursuits

Lubna H. Tahtamouni began her academic journey at the University of Jordan, where she earned a B.Sc. in Biology in June 1997 and an M.Sc. in Biology in April 2000. Her Master's thesis, titled “The Etiological Factors Among 702 Infertile Jordanian Couples,” was supervised by Hameed Al-Hajj, Ph.D. She further pursued a Ph.D. in Developmental Biology at Colorado State University, completing her thesis on “The Role of mDia1 During the Initiation of Polarization and Migration of Chick Embryo Cardiac Fibroblasts” under the guidance of James R. Bamburg, Ph.D.

Professional Endeavors

Dr. Tahtamouni has held numerous academic and administrative positions. She has been a Professor in the Department of Biology and Biotechnology at The Hashemite University in Zarqa, Jordan, since February 2020. Previously, she served as an Associate Professor and Assistant Professor in the same department. Her administrative roles include Chair of the Department of Biology and Biotechnology and Managing the Office of Externally Funded Projects at The Hashemite University. At Colorado State University, she has been an Affiliate Faculty in the Department of Biochemistry and Molecular Biology since August 2023 and served as a Senior Research Scholar and Co-director of the Molecular Biology and Biochemistry REU program.

Contributions and Research Focus on Cancer Cell Biology

Dr. Tahtamouni’s research primarily focuses on understanding the cellular alterations leading to cancer, with specific projects on cell migration, adhesion, metastasis, mitochondrial function, apoptosis, cytoskeleton-related proteins, and cell cycle and anti-tumor drug screening. Additionally, she investigates the role of actin dynamics, mediated by the protein cofilin, in neurodegenerative diseases using induced pluripotent stem cells to model these processes.

Impact and Influence

Dr. Tahtamouni’s contributions to science have been recognized with numerous awards and honors. She was named one of the World's 100 Most Inspirational and Influential Women by the BBC in 2016 and received the Women in Science Hall of Fame award from the US Embassy in Amman, Jordan, in 2015. Her work has earned her fellowships and scholarships from prestigious institutions such as the National Institutes of Health (NIH), the U.S. National Academy of Sciences, and the L'OREAL-UNESCO for Women in Science program.

Academic Cites

Throughout her career, Dr. Tahtamouni has been involved in significant academic publishing and editorial roles. She served as Lead Guest Editor for a special issue on “Molecular Regulation of Cancer Cell Migration, Invasion and Metastasis” in Analytical Cellular Pathology and as an Assistant Editor for the Jordan Journal of Biological Sciences.

Legacy and Future Contributions

Dr. Tahtamouni’s legacy is marked by her dedication to advancing the understanding of cancer and neurodegenerative diseases. Her collaborative efforts span basic, translational, and clinical sciences, significantly impacting these fields. Looking forward, her continued research and mentorship are expected to contribute further to scientific advancements and the development of effective therapeutic strategies.

Teaching and Supervision

Dr. Tahtamouni has extensive teaching experience across various biology and biotechnology courses at The Hashemite University and Colorado State University. She has also supervised numerous training courses, particularly in assisted reproductive techniques and cytogenetics, contributing to the education and professional development of many students and researchers.

Notable Publication:

New Indole-6-Carboxylic Acid Derivatives as Multi-Target Antiproliferative Agents: Synthesis, in Silico Studies, and Cytotoxicity Evaluation 2024 (1)

 

Dr. Sumaira Mubarik – Cancer Science – Best Researcher Award

Posted on by Pencis

Dr. Sumaira Mubarik - Cancer Science - Best Researcher Award

University of Groningen - Netherlands

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Summaira Mubarik embarked on her academic journey with a strong foundation in mathematics, statistics, and computer science. She pursued her Bachelor of Science degree from Punjab University, Pakistan, specializing in Mathematics, Statistics, and Computer Science, which laid the groundwork for her future academic pursuits. Following this, she completed her FSc in Mathematics, Statistics, and Computer Science from BISE, Rawalpindi, Pakistan, further honing her analytical skills and preparing for advanced studies.

PROFESSIONAL ENDEAVORS:

Building upon her educational background, Mubarik pursued higher studies in statistics, earning her Master of Science degree from Arid Agriculture University Rawalpindi, Pakistan, in 2009. Subsequently, she completed her M.Phil, specializing in Statistics, from the same institution in 2012, where she conducted research on Quantile Regression Analysis of Blood Pressure levels for different factors of Adults under the supervision of Dr. Abdush Shakoor. These endeavors marked her entry into the realm of statistical research and analysis.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER SCIENCE

Mubarik's academic journey reached new heights when she pursued her PhD in Statistics at Wuhan University, China, from 2019 to 2021. Under the supervision of Prof. Chuanhua Yu, she delved into the domain of stochastic modeling and prediction of breast cancer risk transitions using the age-period-cohort framework. Her research not only showcased her expertise in applied statistics but also demonstrated a deep commitment to addressing critical issues in biostatistics and epidemiology.

IMPACT AND INFLUENCE:

Throughout her academic career, Mubarik has made significant contributions to the field of statistics, particularly in applied statistics, biostatistics, and disease modeling. Her research endeavors have the potential to impact public health policies and interventions aimed at mitigating the risk of breast cancer. Additionally, her work in stochastic mortality models and survival analysis holds promise for improving our understanding of disease progression and mortality patterns.

ACADEMIC CITATIONS:

Mubarik's research output has garnered attention and recognition within the academic community, as evidenced by her receipt of prestigious scholarships and awards. She was awarded the "Excellent International Student Award" from the Ministry of Education, China, in 2020, along with the Wuhan University Outstanding International Students Scholarship in 2020 and 2021 for her exceptional academic achievements.

LEGACY AND FUTURE CONTRIBUTIONS:

As an Assistant Professor at the University of Groningen, Netherlands, Mubarik continues to pursue her passion for statistics and research. Her expertise in pharma data science and statistics equips her to contribute significantly to the advancement of statistical methodologies in pharmaceutical research and healthcare. With a strong foundation in applied statistics and a focus on epidemiological modeling, Mubarik's future contributions hold the potential to shape the landscape of public health research and policy.

NOTABLE PUBLICATIONS

Estimating disparities of prostate cancer burden and its attributable risk factors for males across the BRICS-plus, 1990–2019: A comparable study of key nations with emerging economies. 2024 (1)

Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. 2024 (5)

Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. 2024 (1)

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. 2024 (4)

Temporal patterns of cancer burden in Asia, 1990–2019: a systematic examination for the Global Burden of Disease 2019 study 2024

Prof Dr. TatianaTilli – Oncology and Precision Medicine – Women Researcher Award

Posted on by Pencis

Prof Dr. TatianaTilli - Oncology and Precision Medicine - Women Researcher Award

Oswaldo Cruz Foundation - Brazil

AUTHOR PROFILE

Google Scholar
Scopus
Orcid

EARLY ACADEMIC PURSUITS

Tatiana Martins Tilli pursued her Doctorate in Medicine from the Instituto Nacional de Câncer (INCA) in Rio De Janeiro, Brazil. Her research focused on the functional characterization of splicing variant isoforms of osteopontin in ovarian and prostate carcinomas. This research was conducted under the guidance of Dr. Etel Rodrigues Pereira Gimba and Dr. Akeila Bellahcène at the Université de Liège during her Sandwich Doctorate. The study highlighted the significance of osteopontin as a molecular marker in ovarian and prostate cancers, emphasizing the role of splicing isoforms.Prior to her doctorate, Dr. Tilli completed her Master's in Medicine at INCA. Her research focused on autoantibodies against osteopontin as potential serum markers in neoplasms. This research further underscored the importance of osteopontin as a molecular marker in oncology and provided insights into its immunological aspects.

PROFESSIONAL ENDEAVORS

After completing her doctorate, Dr. Tilli pursued her postdoctoral research at the University of Alberta in Edmonton, Canada. Her postdoctoral work encompassed areas such as Systems Biology, Cellular Biology, and Molecular Biophysics. This period allowed her to expand her research expertise and collaborate with international experts in her field.Currently, Dr. Tilli serves as a public servant in a full-time and exclusive capacity, dedicating 40 hours weekly as a researcher. Her role involves conducting research in the domain of human health, building on her extensive academic background and professional experience.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY AND PRECISION MEDICINE

Dr. Tilli's research has primarily revolved around osteopontin, a molecule of significant interest in oncology. Her studies have explored the functional characterization of splicing variant isoforms of osteopontin and the potential of autoantibodies against osteopontin as serum markers in neoplasms. These research endeavors have contributed significantly to the understanding of molecular markers in ovarian and prostate cancers.

IMPACT AND INFLUENCE

Dr. Tilli's work has had a substantial impact on the field of oncology, particularly in the identification and characterization of molecular markers in ovarian and prostate cancers. Her research findings have been influential in shaping the current understanding of osteopontin's role in cancer biology and its potential applications in diagnostic and therapeutic strategies.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Tatiana Martins Tilli has established herself as a leading researcher in the field of oncology, with a focus on molecular markers, particularly osteopontin. Her legacy lies in her significant contributions to understanding the role of osteopontin in ovarian and prostate cancers.In the future, Dr. Tilli is expected to continue her groundbreaking research, further exploring the potential applications of osteopontin and its variants in cancer diagnosis, prognosis, and targeted therapy. Her continued dedication to advancing the field of oncology promises to yield further impactful contributions to human health.

NOTABLE PUBLICATIONS

Unlocking Overexpressed Membrane Proteins to Guide Breast Cancer Precision Medicine. 2024

Aptamer-Based Recognition of Breast Tumor Cells: A New Era for Breast Cancer Diagnosis. 2024

Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug. 2022

Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment and Decision Making. 2021

Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications. 2021

Assoc Prof Dr.Tiruveedula Gopi Krishna – Cancer Science – Best Researcher Award

Posted on by Pencis

Assoc Prof Dr.Tiruveedula Gopi Krishna - Cancer Science - Best Researcher Award

Adama Science and Technology University - Ethiopia

AUTHOR PROFILE

Google Scholar

Orcid

EARLY ACADEMIC PURSUITS

Dr. Tiruveedula Gopikrishna began his academic journey in the field of Computer Science and Engineering. His early academic pursuits laid the foundation for his future contributions in the realm of technology and information sciences.

PROFESSIONAL ENDEAVORS

Having demonstrated a keen interest in the field, Dr. Gopikrishna embarked on a professional journey that led him to the position of Assistant Professor and subsequently Associate Professor at Adama Science & Technology University in Ethiopia. His commitment to academia reflects in his multifaceted roles and responsibilities.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER SCIENCE

Dr. Gopikrishna's expertise encompasses a diverse range of subjects, including Data Science, Big Data, Artificial Intelligence, Machine Learning, Deep Learning, Distributed Systems, Data Warehousing, Data Mining, Cloud Computing, C, Python, C++, Java, Web Technologies, and SQL. His research focus extends to critical areas such as Big Data Analytics and Visualization, Software Testing Methodologies, Middleware, and the intersection of big data with cloud computing.

IMPACT AND INFLUENCE

Dr. Gopikrishna's impact is evident in the significant contributions he has made to the academic and research community. His influence extends beyond the classroom, shaping the minds of aspiring technologists and researchers under his guidance.

ACADEMIC CITES

The academic prowess of Dr. Gopikrishna is underscored by his extensive experience in teaching undergraduate and postgraduate subjects. He has been instrumental in guiding 56 undergraduate projects and supervising 4 master's degree theses, showcasing his commitment to fostering academic excellence.

LEGACY AND FUTURE CONTRIBUTIONS

As an Associate Professor, Dr. Gopikrishna has already established a legacy in academia. His dedication to shaping the next generation of tech professionals and researchers is evident. Looking forward, his future contributions are poised to further enrich the fields of Computer Science and Information Technology, leaving an indelible mark on the academic landscape.

NOTABLE PUBLICATIONS

An Improved Switch Migration Method Based Efficient Load Balancing for Multiple Controllers in Software Defined Network. 2023

DDoS Attack Detection and Classification Using Hybrid Model for Multi-controller SDN. 2023 (3)

Classification of Brain Tumor Types on Magnetic Resonance Images Using Hybrid Deep Learning Approach with Radial Basis Function Neural Network. 2022

Breast Cancer Classification from Mammogram Images Using Extreme Learning Machine-Based DenseNet121 Model. 2022 (5)

Designing and Developing Bilingual Chatbot for AssistingEthio-Telecom Customers on Customer Services. 2022

Cancer Treatment, Therapies and Nursing

Posted on by Pencis

Cancer Treatment, Therapies and Nursing

Introduction: Cancer Treatment, Therapies, and Nursing represent the multifaceted approach to addressing cancer, combining cutting-edge medical interventions, supportive care, and compassionate nursing to improve patient outcomes and enhance their quality of life. These components are integral in the comprehensive battle against cancer.

Subtopics in Cancer Treatment, Therapies, and Nursing:

Oncology Nursing and Patient Care: Explore the pivotal role of oncology nurses in providing personalized care, managing symptoms, and offering emotional support to cancer patients throughout their treatment journey.

Surgery in Cancer Treatment: Delve into the various surgical procedures used to remove tumors, biopsy tissues, and reconstruct affected areas, and their significance in the overall cancer treatment plan.

Radiation Therapy: Understand the principles and advancements in radiation therapy, including techniques like IMRT and proton therapy, and how they target cancer cells while minimizing damage to healthy tissue.

Chemotherapy and Targeted Therapies: Examine the different types of chemotherapy and targeted therapies, their mechanisms of action, and the evolving landscape of drug development in cancer treatment.

Palliative and Supportive Care: Explore the importance of palliative care in managing cancer-related symptoms, improving the patient’s quality of life, and addressing end-of-life considerations, alongside the crucial role of supportive care services.

Integrative and Complementary Therapies: Investigate complementary approaches such as acupuncture, yoga, and mindfulness, which can complement traditional cancer treatments and aid in symptom management and emotional well-being.

Precision Medicine in Oncology: Understand how precision medicine tailors cancer treatment to an individual’s genetic and molecular profile, optimizing therapy selection and minimizing side effects.

Survivorship Programs: Learn about survivorship programs that focus on the long-term health and well-being of cancer survivors, addressing physical, psychological, and social aspects of post-treatment life.

Emerging Therapies and Clinical Trials: Explore promising experimental therapies and the importance of clinical trials in advancing cancer treatment options, as well as the roles

 

Medical Oncology

Posted on by Pencis

Medical Oncology

Introduction to Medical Oncology: Medical Oncology is a specialized branch of medicine dedicated to the diagnosis, treatment, and management of cancer. This field plays a pivotal role in improving the lives of cancer patients through various treatment modalities and cutting-edge research. Within the realm of Medical Oncology, several key subtopics are essential for understanding and addressing the complexities of cancer care:

Chemotherapy and Targeted Therapies: Chemotherapy involves the use of drugs to kill or slow the growth of cancer cells, while targeted therapies focus on specific molecular abnormalities within cancer cells. Understanding these treatment options is crucial for medical oncologists to tailor therapies for individual patients.

Immunotherapy: Immunotherapy harnesses the body’s immune system to combat cancer. This groundbreaking approach has revolutionized cancer treatment by enhancing the body’s natural defenses against cancer cells.

Precision Medicine: Precision medicine in oncology involves customizing treatment plans based on a patient’s unique genetic and molecular profile. It allows for more personalized and effective cancer treatments, minimizing side effects.

Palliative Care: Palliative care in Medical Oncology is vital for improving the quality of life for cancer patients. It focuses on symptom management, pain relief, and emotional support to enhance patients’ overall well-being.

Clinical Trials and Research: Ongoing research and clinical trials are at the forefront of Medical Oncology. Investigating new treatments, therapies, and breakthroughs in cancer care is essential for improving patient outcomes and advancing the field.

These subtopics illustrate the multidimensional nature of Medical Oncology, where a comprehensive approach is taken to address the complexities of cancer treatment and patient care.